Invivyd (IVVD) Net Equity Issued and Repurchased (2021 - 2025)
Invivyd (IVVD) posted Net Equity Issued and Repurchased of $10.9 million for Q4 2025, up 13874.36% on a QoQ basis from $78000.0 in Q2 2025, and up 33962.5% year-over-year from N/an in Q4 2024.
Invivyd (IVVD) Net Equity Issued and Repurchased (2021 - 2025) Analysis & Trends
Invivyd's Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $10.9 million for Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 33962.5% year-over-year to $10.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.1 million (up 4856.95% YoY) and the FY2025 annual result came in at $254000.0, up 13.9% from the prior year.
- Net Equity Issued and Repurchased was $10.9 million for Q4 2025 at Invivyd, up from $78000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $335.2 million in Q4 2021 and bottomed at -$335.3 million in Q3 2021.
- A 5-year average of $776866.7 and a median of $75000.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 99.96% — and 2025, when it jumped 33962.5%.
- Invivyd's Net Equity Issued and Repurchased stood at $335.2 million in 2021, then sank by 99.96% to $120000.0 in 2022, then slumped by 63.33% to $44000.0 in 2023, then dropped by 27.27% to $32000.0 in 2024, then soared by 33962.5% to $10.9 million in 2025.
- Business Quant data shows IVVD's Net Equity Issued and Repurchased at $10.9 million in Q4 2025, $78000.0 in Q2 2025, and $44000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 141.90 Mn |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 10.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.90 Mn |
| Dec 31, 2025 | 10.90 Mn |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 57,000.00 |
| Sep 30, 2023 | 57,000.00 |
| Jun 30, 2023 | 56,000.00 |
| Jun 30, 2023 | 56,000.00 |